Search Results

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + PDCT demonstrated a higher overall response rate (ORR) (51.3%) compared to NIVO + PDCT […]

The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line treatment. However, the COMBO arm did not improve PFS, with median PFS being shorter […]

Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, Germany. After graduating from Hannover Medical School in 2002, he completed a surgery and urology residency at the Eberhard Karls University, in Tübingen, followed by a research fellowship at the Miller School of Medicine, Miami, […]

Significant advancements in bladder cancer research emerged from ASCO 2024. To understand these, as well as the other key trials and highlights from the meeting, we spoke with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas. In this interview, Prof. Grivas delves into the findings from the EV-302 (NCT04223856), EV-101 (NCT02091999), EV-201 (NCT03219333), EV-301 (NCT03474107), CheckMate 901 (NCT03036098) and other trials, offering his valuable insights into the impact the results could have on clinical practice, and particularly in the treatment of bladder

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change […]